Zur Rose Group AG
SIX:ROSE
Intrinsic Value
Zur Rose Group AG engages in the operation of an e-commerce pharmacy. [ Read More ]
The intrinsic value of one ROSE stock under the Base Case scenario is 63.57 CHF. Compared to the current market price of 32.3 CHF, Zur Rose Group AG is Undervalued by 49%.
Valuation Backtest
Zur Rose Group AG
Run backtest to discover the historical profit from buying and selling ROSE stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Zur Rose Group AG
Current Assets | 395.9m |
Cash & Short-Term Investments | 156.4m |
Receivables | 145.3m |
Other Current Assets | 94.2m |
Non-Current Assets | 703.6m |
Long-Term Investments | 30.1m |
PP&E | 96.8m |
Intangibles | 571.9m |
Other Non-Current Assets | 4.8m |
Current Liabilities | 241.3m |
Accounts Payable | 112.8m |
Accrued Liabilities | 39.7m |
Other Current Liabilities | 88.9m |
Non-Current Liabilities | 507.3m |
Long-Term Debt | 493.1m |
Other Non-Current Liabilities | 14.2m |
Earnings Waterfall
Zur Rose Group AG
Revenue
|
1.6B
CHF
|
Cost of Revenue
|
-1.4B
CHF
|
Gross Profit
|
245.6m
CHF
|
Operating Expenses
|
-379.5m
CHF
|
Operating Income
|
-133.9m
CHF
|
Other Expenses
|
-37.2m
CHF
|
Net Income
|
-171.1m
CHF
|
Free Cash Flow Analysis
Zur Rose Group AG
What is Free Cash Flow?
ROSE Profitability Score
Profitability Due Diligence
Zur Rose Group AG's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Zur Rose Group AG's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
ROSE Solvency Score
Solvency Due Diligence
Zur Rose Group AG's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Score
Zur Rose Group AG's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ROSE Price Targets Summary
Zur Rose Group AG
Shareholder Return
ROSE Price
Zur Rose Group AG
Average Annual Return | 55.88% |
Standard Deviation of Annual Returns | 97.12% |
Max Drawdown | -95% |
Market Capitalization | 374.9m CHF |
Shares Outstanding | 12 537 287 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Zur Rose Group AG engages in the operation of an e-commerce pharmacy. The company is headquartered in Frauenfeld, Thurgau and currently employs 2,131 full-time employees. The company went IPO on 2017-07-06. The firm focuses on the wholesale trade of medicines, as well as operation of a mail-order pharmacy. The firm's activities are divided into two business segments: Zur Rose and DocMorris. The Zur Rose division includes wholesale business and provides drugs to medical doctors, health insurance companies, hospitals and healthcare companies, among others. The DocMorris division manages the mail-order business for drug retail. The firm operates in Switzerland, Germany and the Netherlands through a number of subsidiaries, such as Zur Rose Suisse AG, Zur Rose Pharma GmbH, BlueCare AG, DocMorris NV, Eurapon Pharmahandel GmbH and Vitalsana BV.
Contact
IPO
Employees
Officers
The intrinsic value of one ROSE stock under the Base Case scenario is 63.57 CHF.
Compared to the current market price of 32.3 CHF, Zur Rose Group AG is Undervalued by 49%.